Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Dec 2017
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacodynamics; Registrational
- Acronyms NuProtect
- Sponsors Octapharma
- 23 Aug 2017 Interim results (n=66) published in an Octapharma Media Release.
- 23 Aug 2017 According to an Octapharma media release, Interim results were published in the medical journal Haemophilia.
- 10 Jul 2017 Interim results were presented at the International Society on Thrombosis and Haemostasis (ISTH) Congress.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History